Myovant Sciences Ltd

NYSE:MYOV   3:59:58 PM EDT
-0.49 (-2.45%)
Products, Regulatory, Earnings Announcements

Myovant Sciences Announces Results Of Additional Secondary Endpoint Of Castration Resistance-Free Survival From Phase 3 Hero Study Of Relugolix In Advanced Prostate Cancer

Published: 09/29/2020 14:04 GMT
Myovant Sciences Ltd (MYOV) - Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-free Survival From Phase 3 Hero Study of Relugolix in Advanced Prostate Cancer.
Myovant Sciences Ltd - Relugolix Did Not Achieve Statistical Superiority for Castration Resistance-free Survival.
Myovant Sciences- Incidence of Adverse Events in Subgroup of Men With Metastatic Disease Was Consistent With That Observed in Primary Analysis of Hero.
Myovant Sciences Ltd - Relugolix Also Met Six Key Secondary Endpoints.
Revenue is expected to be $21.8 Million
Adjusted EPS is expected to be -$0.92

Next Quarter Revenue Guidance is expected to be $48.24 Million
Next Quarter EPS Guidance is expected to be -$0.61

More details on our Analysts Page.